Pacritinib

Drug Profile

Pacritinib

Alternative Names: ONX-0803; Pacritinibum; SB-1518

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator S*BIO
  • Developer Cardiff University; CTI BioPharma; National Cancer Research Institute; Ohio State University Comprehensive Cancer Center; S*BIO; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Macrocyclic compounds; Polycyclic bridged compounds; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Colony stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders; Myelofibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Myelofibrosis
  • Phase II Acute myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Myeloproliferative disorders
  • Phase I Haematological disorders
  • Preclinical Chronic myeloid leukaemia
  • Discontinued Lymphoma

Most Recent Events

  • 09 Jan 2017 Pacritinib is available for licensing in territories excluding USA as of 09 Jan 2017. www.ctibiopharma.com
  • 05 Jan 2017 Phase-I clinical trials in Haematological disorders (In volunteers) in USA (PO)
  • 05 Jan 2017 Phase-I clinical trials in Myelofibrosis in Moldova (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top